BioNTech SE Stock

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-12 EDT 5-day change 1st Jan Change
86.48 USD -0.61% Intraday chart for BioNTech SE -4.46% -18.06%

Financials

Sales 2024 * 2.8B 2.98B 4.1B Sales 2025 * 2.83B 3.01B 4.15B Capitalization 19.59B 20.84B 28.71B
Net income 2024 * -457M -486M -670M Net income 2025 * -353M -376M -517M EV / Sales 2024 * 1.88 x
Net cash position 2024 * 14.33B 15.24B 21B Net cash position 2025 * 14.09B 14.99B 20.65B EV / Sales 2025 * 1.94 x
P/E ratio 2024 *
-39.6 x
P/E ratio 2025 *
-44 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.61%
1 week-4.46%
Current month-6.25%
1 month-7.95%
3 months-16.50%
6 months-16.51%
Current year-18.06%
More quotes
1 week
85.60
Extreme 85.6
92.48
1 month
85.21
Extreme 85.2129
94.44
Current year
85.21
Extreme 85.2129
114.70
1 year
85.21
Extreme 85.2129
129.10
3 years
85.21
Extreme 85.2129
464.00
5 years
12.53
Extreme 12.525
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 69 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
Date Price Change Volume
24-04-12 86.48 -0.61% 726,723
24-04-11 87.01 -1.85% 574,536
24-04-10 88.65 -1.55% 429,437
24-04-09 90.05 +0.83% 627,103
24-04-08 89.31 -1.34% 646,997

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
81.3 EUR
Average target price
106.9 EUR
Spread / Average Target
+31.50%
Consensus